Who is sponsoring NCT04690283?

NCT04690283 is sponsored by Nanjing NingQi Medicine Science and Technology Co., Ltd..

What drugs are being tested in NCT04690283?

Interventions in NCT04690283: Mimetic granules of Yiqi-Wenjing prescriptions, Huangqi-Guizhi-Wuwu granules, Danggui-Sini granules.

What condition does NCT04690283 study?

NCT04690283 studies Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer.

Is NCT04690283 still recruiting?

NCT04690283 is currently status unknown. Last updated 30 December 2020.

Last reviewed 2020-12-30 · How we verify

NCT04690283: YWPPEOPNCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

Status unknown Phase 3 Last updated 30 December 2020

What this trial tests

Phase 3 trial testing Mimetic granules of Yiqi-Wenjing prescriptions in Chemotherapy-induced Peripheral Neuropathy in 360 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
1 July 2022

1 October 2022

Quick facts

Lead sponsor	Nanjing NingQi Medicine Science and Technology Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	360
Start date	1 January 2021
Primary completion	1 July 2022
Estimated completion	1 October 2022

Drugs / interventions tested

Mimetic granules of Yiqi-Wenjing prescriptions — full drug profile →
Huangqi-Guizhi-Wuwu granules — full drug profile →
Danggui-Sini granules — full drug profile →

Conditions studied

Chemotherapy-induced Peripheral Neuropathy — all drugs for Chemotherapy-induced Peripheral Neuropathy →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Nanjing NingQi Medicine Science and Technology Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical trial of Yiqi Wenjing prescriptions for Preventing Oxaliplatin-induced Peripheral Neuropathy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.
Kee JX, Yau JNN, Kumar Muthuramalingam RP, Wang X, et al · · 2025 · cited 6× · PMID 40985211 · DOI 10.1021/acs.chemrev.5c00041
Interplay Between Traditional and Scientific Knowledge: Phytoconstituents and Their Roles in Lung and Colorectal Cancer Signaling Pathways.
Imtiaz I, Schloss J, Bugarcic A. · · 2025 · cited 6× · PMID 40149916 · DOI 10.3390/biom15030380
Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z, Chen C, Gu J, Song Z, et al · · 2023 · cited 5× · PMID 37964212 · DOI 10.1186/s12885-023-11541-7
Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.
Gu Z, Wei G, Zhu L, Zhu L, et al · · 2021 · cited 5× · PMID 34630609 · DOI 10.1155/2021/5551568

Verify or expand the search:

Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy

Currently open trials in the same condition.

NCT07177820 — VGAIT for Chemotherapy-induced Peripheral Neuropathy · NA · recruiting
NCT07072468 — Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) · Phase 2 · recruiting
NCT06389721 — Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy · recruiting
NCT06405542 — Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) · Phase 1 · active not recruiting
NCT06162403 — Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longi · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04690283 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing NingQi Medicine Science and Technology Co., Ltd.
Last refreshed: 30 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04690283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing